Literature DB >> 1677456

Evidence for mu opiate receptors on inhibitory terminals in area CA1 of rat hippocampus.

N A Lambert1, N L Harrison, T J Teyler.   

Abstract

The mechanism of disinhibition produced by opioid peptides was studied using intracellular recording in area CA1 of rat hippocampal slices. The mu-selective opioid peptide [D-Ala2,N-Me-Phe4,Gly-ol5]-enkephalin (DAGO) reversibly depressed directly-activated, monosynaptic inhibitory postsynaptic potentials (IPSPs) evoked in the presence of the excitatory amino acid receptor antagonists 6,7-dinitroquinoxaline-2,3-dione (DNQX) and D,L-2-amino-5-phosphonovalerate (APV) in a naloxone-sensitive manner. Depression of monosynaptic inhibitory postsynaptic potentials (IPSPs) by DAGO was not prevented by 1-2 mM Ba2+. DAGO reversibly depressed monosynaptic IPSPs when applied locally close to the recording site, but was ineffective when applied close to the stimulating site in stratum radiatum. These results suggest that DAGO disinhibits pyramidal neurons in area CA1 of the rat hippocampus by activating mu opiate receptors located on the terminals of inhibitory neurons, and by a Ba(2+)-insensitive mechanism.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677456     DOI: 10.1016/0304-3940(91)90831-d

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  10 in total

1.  Effects of the putative P-type calcium channel blocker, R,R-(-)-daurisoline on neurotransmitter release.

Authors:  P C Waldmeier; P Wicki; W Fröstl; H Bittiger; J J Feldtrauer; P A Baumann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-12       Impact factor: 3.000

2.  mu-Opioid receptors are localized to extrasynaptic plasma membranes of GABAergic neurons and their targets in the rat nucleus accumbens.

Authors:  A L Svingos; A Moriwaki; J B Wang; G R Uhl; V M Pickel
Journal:  J Neurosci       Date:  1997-04-01       Impact factor: 6.167

3.  Fast synaptic transmission mediated by P2X receptors in CA3 pyramidal cells of rat hippocampal slice cultures.

Authors:  M Mori; C Heuss; B H Gähwiler; U Gerber
Journal:  J Physiol       Date:  2001-08-15       Impact factor: 5.182

4.  mu-Opioid receptors modulate NMDA receptor-mediated responses in nucleus accumbens neurons.

Authors:  G Martin; Z Nie; G R Siggins
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

5.  Remifentanil administration reveals biphasic phMRI temporal responses in rat consistent with dynamic receptor regulation.

Authors:  Christina H Liu; Doug N Greve; Guangping Dai; John J A Marota; Joseph B Mandeville
Journal:  Neuroimage       Date:  2006-12-13       Impact factor: 6.556

6.  Low ethanol concentrations enhance GABAergic inhibitory postsynaptic potentials in hippocampal pyramidal neurons only after block of GABAB receptors.

Authors:  F J Wan; F Berton; S G Madamba; W Francesconi; G R Siggins
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-14       Impact factor: 11.205

7.  Mechanism of mu-opioid receptor-mediated presynaptic inhibition in the rat hippocampus in vitro.

Authors:  M Capogna; B H Gähwiler; S M Thompson
Journal:  J Physiol       Date:  1993-10       Impact factor: 5.182

8.  Extracellular free potassium and calcium during synchronous activity induced by 4-aminopyridine in the juvenile rat hippocampus.

Authors:  M Avoli; J Louvel; I Kurcewicz; R Pumain; M Barbarosie
Journal:  J Physiol       Date:  1996-06-15       Impact factor: 5.182

9.  High-threshold Ca2+ currents in rat hippocampal interneurones and their selective inhibition by activation of GABA(B) receptors.

Authors:  N A Lambert; W A Wilson
Journal:  J Physiol       Date:  1996-04-01       Impact factor: 5.182

10.  Insulin Bidirectionally Alters NAc Glutamatergic Transmission: Interactions between Insulin Receptor Activation, Endogenous Opioids, and Glutamate Release.

Authors:  Tracy L Fetterly; Max F Oginsky; Allison M Nieto; Yanaira Alonso-Caraballo; Zuleirys Santana-Rodriguez; Carrie R Ferrario
Journal:  J Neurosci       Date:  2021-01-29       Impact factor: 6.709

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.